New research published in eBioMedicine provides the strongest evidence to date that long COVID is linked to physical injury within the brain’s dopamine system. Researchers at the Centre for Addiction and Mental Health (CAMH) in Canada used PET imaging to identify reduced dopamine nerve terminal density, offering a potential biological explanation for persistent symptoms like fatigue, cognitive impairment, and lack of motivation.
The Biological Mechanism of Long COVID Symptoms
For the approximately nine million adults in the United States and 5% of the global population living with long COVID, the condition has often lacked clear diagnostic markers. However, the study from CAMH suggests these symptoms are not merely behavioral or psychological. Researchers utilized positron emission tomography (PET) imaging to compare individuals with long COVID against healthy control participants.
The imaging revealed significantly lower levels of dopamine neuron markers throughout the striatum. This brain region is critical for managing movement, learning, cognition, and motivation. The loss of nerve terminal density provides a measurable, objective basis for the neurological struggles patients report months after an initial SARS-CoV-2 infection.
The study found a direct correlation between specific brain regions and patient symptoms. Lower dopamine markers in the ventral striatum were linked to a loss of motivation, while reductions in the dorsal putamen correlated with slower physical movement.
Connecting Inflammation to Dopamine Injury
This study builds on previous findings from the same research team, which identified elevated brain inflammation in long COVID patients, particularly in regions rich in dopamine-producing neurons. While inflammation is known to damage these neurons in other neurological disorders, this research provides the first direct link between that inflammatory process and measurable dopamine system injury in the context of COVID-19.
By shifting the focus toward dopamine dysfunction, the findings challenge the view that long COVID is solely an inflammatory condition. Instead, it suggests a secondary, structural injury to the brain’s signaling pathways that persists long after the virus has cleared.
Future Trends: Toward Mechanism-Based Treatments
The identification of dopamine system injury opens the door for targeted clinical interventions. Because several medications already exist to enhance dopamine signaling or inhibit dopamine metabolism, researchers are now looking toward repurposing these drugs for long COVID patients.
The team at CAMH is currently collaborating with the University Health Network to launch a clinical trial. The study will evaluate whether therapies designed to improve dopamine function can effectively reduce fatigue and improve memory in those suffering from persistent symptoms. If these trials succeed, it would represent a transition from managing symptoms to treating the underlying biological mechanism of the condition.
Keep an eye on upcoming clinical trial registries for updates on dopamine-focused therapies. As research progresses, patients should consult with specialists about how emerging neurological findings may influence future treatment options.
Frequently Asked Questions
Is long COVID considered a neurological disorder?
Yes, the recent research from CAMH supports the conclusion that long COVID involves measurable injury to the brain’s dopamine system, which controls motivation, movement, and cognition.
Why haven’t there been effective treatments until now?
Treatments have been difficult to develop because the biological mechanisms driving long COVID symptoms were poorly understood. This new evidence provides a specific target—the dopamine system—for future clinical trials.
What are the common symptoms linked to dopamine loss?
Patients in the study reported fatigue, lack of motivation, memory impairment, and slowed movement, all of which matched the regions of the brain where dopamine markers were found to be lower.
Have you or a loved one been impacted by long COVID symptoms? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates on neurological research and clinical trial progress.
